CL2022001067A1 - Anticuerpos antihemaglutinina y métodos de uso de estos - Google Patents

Anticuerpos antihemaglutinina y métodos de uso de estos

Info

Publication number
CL2022001067A1
CL2022001067A1 CL2022001067A CL2022001067A CL2022001067A1 CL 2022001067 A1 CL2022001067 A1 CL 2022001067A1 CL 2022001067 A CL2022001067 A CL 2022001067A CL 2022001067 A CL2022001067 A CL 2022001067A CL 2022001067 A1 CL2022001067 A1 CL 2022001067A1
Authority
CL
Chile
Prior art keywords
antibodies
influenza
methods
bind
hemagglutinin
Prior art date
Application number
CL2022001067A
Other languages
English (en)
Inventor
Christos Kyratsous
Alina Baum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022001067A1 publication Critical patent/CL2022001067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)

Abstract

En la presente descripción se proporcionan anticuerpos monoclonales, o fragmentos de unión al antígeno de estos, que se unen a la proteína hemaglutinina (HA) de influenza B, composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos son útiles para inhibir o neutralizar la actividad del virus de influenza B, y proporcionan así un medio para tratar o prevenir la infección por influenza en seres humanos. En la presente descripción también se proporciona el uso de uno o más anticuerpos que se unen a la HA de influenza B para prevenir el acoplamiento viral y/o la entrada en células huésped. Los anticuerpos pueden usarse profilácticamente o terapéuticamente y pueden usarse solos o en combinación con uno o más de otros agentes o vacunas antivirales.
CL2022001067A 2019-10-28 2022-04-27 Anticuerpos antihemaglutinina y métodos de uso de estos CL2022001067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US202063094170P 2020-10-20 2020-10-20

Publications (1)

Publication Number Publication Date
CL2022001067A1 true CL2022001067A1 (es) 2023-01-27

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001067A CL2022001067A1 (es) 2019-10-28 2022-04-27 Anticuerpos antihemaglutinina y métodos de uso de estos

Country Status (14)

Country Link
US (2) US11773156B2 (es)
EP (1) EP4051707A1 (es)
JP (1) JP7611908B2 (es)
KR (1) KR20220088446A (es)
CN (1) CN114761428A (es)
AU (2) AU2020374878B2 (es)
BR (1) BR112022007923A2 (es)
CA (1) CA3153944A1 (es)
CL (1) CL2022001067A1 (es)
CO (1) CO2022005281A2 (es)
IL (1) IL292353A (es)
MY (1) MY207220A (es)
PH (1) PH12022550963A1 (es)
WO (1) WO2021086899A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EP2814841A4 (en) * 2012-01-31 2015-06-17 Univ Osaka HUMAN MONOCLONAL ANTIBODIES FOR WIDE PROTECTION AGAINST INFLUENZA B VIRUS AND METHOD OF USE THEREOF
EP2825036B1 (en) * 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) * 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
TW201620932A (zh) * 2014-03-27 2016-06-16 建南德克公司 抗－ｂ型流感病毒血球凝集素抗體及其使用方法
MX392761B (es) * 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
HUE056407T2 (hu) * 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
CN106243218B (zh) 2015-06-03 2020-05-15 厦门大学 抗Flu B的广谱单克隆抗体及其用途
MX2018015755A (es) * 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) * 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11780907B2 (en) * 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin

Also Published As

Publication number Publication date
CO2022005281A2 (es) 2022-05-10
AU2020374878B2 (en) 2025-10-16
US11773156B2 (en) 2023-10-03
US20210171612A1 (en) 2021-06-10
IL292353A (en) 2022-06-01
US20240083983A1 (en) 2024-03-14
CA3153944A1 (en) 2021-05-06
JP2022553703A (ja) 2022-12-26
JP7611908B2 (ja) 2025-01-10
AU2020374878A1 (en) 2022-04-28
WO2021086899A1 (en) 2021-05-06
KR20220088446A (ko) 2022-06-27
EP4051707A1 (en) 2022-09-07
MY207220A (en) 2025-02-06
CN114761428A (zh) 2022-07-15
BR112022007923A2 (pt) 2022-07-26
PH12022550963A1 (en) 2023-09-25
AU2025271140A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
CL2020000498A1 (es) Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920)
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
MX2019000761A (es) Anticuerpos anti-virus del zika y metodos de uso.
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
CL2023001462A1 (es) Anticuerpos ampliamente neutralizantes contra la neuraminidasa de influenza
CL2022001067A1 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
MX2020007050A (es) Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
AR103054A1 (es) Anticuerpos humanos para hemaglutinina influenza
AR104480A1 (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
EA202191973A2 (ru) Человеческие антитела к гликопротеину вируса эбола